Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE
The Journal of Allergy and Clinical Immunology: In Practice · 2025
DOI: 10.1016/j.jaip.2025.02.004 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Matthew Greenhawt und 59 weiteren Autor:innen. Beteiligte Einrichtung: Section of Allergy and Immunology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo. E…. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Desensitization, Immunologic, Allergens, Antigens, Plant. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years. OBJECTIVE: To assess the interim efficacy and safety of VP250 from the first year of the EPITOPE open-label extension (OLE) study. METHODS: Eligible participants enrolled in the OLE study for up to 3 years of total treatment with annual double-blind, placebo-controlled food challenges (DBPCFCs) and safety assessments; here we report the first-year OLE (year 2) results. RESULTS: A total of 266 EPITOPE participants enrolled in the OLE study; 244 underwent month 24 DBPCFC (n = 166 VP250; n = 78 placebo). After 24 months of VP250, 81.3% reached an eliciting dose (ED) ≥1000 mg, 63.8% reached an ED ≥2000 mg, and 55.9% completed the DBPCFC (cumulative dose: 3444 mg) without meeting stopping criteria. No treatment-related anaphylaxis or serious treatment-related adverse events occurred during year 2 in this treatment arm. Local application-site reactions occurred less frequently in year 2 versus year 1. In placebo-treated EPITOPE participants, outcomes after 1 year of open-label VP250 were consistent with EPITOPE treatment results: 62.7% reached an ED ≥1000 mg, 36.5% reached an ED ≥2000 mg, and 28.4% completed the DBPCFC without meeting stopping criteria; and there was 1 treatment-related anaphylaxis event. CONCLUSIONS: Two years of VP250 in young peanut-allergic children demonstrated continued increases in treatment effect without new safety signals. This supports the potential of VP250 as a safe and effective treatment for peanut allergy in young children. CLINICALTRIALS: GOV: NCT03859700.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Allergy and Immunology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo. Electronic address: Matthew.Greenhawt@childrenscolorado.org.
- UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pa.
- Department of Pediatrics, Division of Immunology, Allergy, and Retrovirology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas.
- Department of Pediatrics, Division of Allergy and Pulmonology, Erasmus MC Sophia Children's Hospital, Rotterdam, the Netherlands.
- Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom.
- Section of Allergy, Immunology, and Rheumatology, Department of Pediatrics, CHU Sainte-Justine and Université de Montréal, Montreal, QC, Canada.
Zitieren
APA
Greenhawt, M., Albright, D., Anvari, S., Arends, N., Arkwright, P. D., Bégin, P., Blümchen, K., Brown-Whitehorn, T., Cassell, H., Chan, E. S., Ciaccio, C. E., Deschildre, A., Divaret-Chauveau, A., Dorris, S., Dorsey, M., Du Toit, G., Eiwegger, T., Erlewyn-Lajeunesse, M., Fleischer, D. M., …, & Sampson, H. A. (2025). Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2025.02.004
Vancouver
Greenhawt M, Albright D, Anvari S, Arends N, Arkwright PD, Bégin P, et al. Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2025.02.004
BibTeX
@article{Greenhawt2025,
author = {Greenhawt, Matthew and Albright, Deborah and Anvari, Sara and Arends, Nicolette and Arkwright, Peter D and Bégin, Philippe and Blümchen, Katharina and Brown-Whitehorn, Terri and Cassell, Heather and Chan, Edmond S and Ciaccio, Christina E and Deschildre, Antoine and Divaret-Chauveau, Amandine and Dorris, Stacy and Dorsey, Morna and Du Toit, George and Eiwegger, Thomas and Erlewyn-Lajeunesse, Michel and Fleischer, David M and Ford, Lara S and Garcia-Lloret, Maria and O'B Hourihane, Jonathan and Jay, Nicola and Jones, Stacie M and Kim, Edwin H and Kloepfer, Kirsten and Leonard, Stephanie and Lezmi, Guillaume and Lieberman, Jay and Lomas, Jeanne and Makhija, Melanie and O'Sullivan, Michael and Parrish, Christopher and Peake, Jane and Perrett, Kirsten P and Petroni, Daniel and Pongracic, Jacqueline A and Quinn, Patrick and Robison, Rachel G and Sanders, Georgiana and Schneider, Lynda and Sharma, Hemant and Sindher, Sayantani B and Trujillo, Juan and Turner, Paul J and Tuttle, Katherine and Upton, Julia and Varshney, Pooja and Vickery, Brian P and Vogelberg, Christian and Wainstein, Brynn and Wang, Julie and Wood, Robert and Bee, Katharine J and Campbell, Dianne E and Green, Todd D and Rouissi, Rihab and Bahnson, Henry T and Bois, Timothée and Sampson, Hugh A},
title = {Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2025},
doi = {10.1016/j.jaip.2025.02.004}
}
EUVIMED